CN114945353A - 高亲脂性生理活性物质的控释制剂 - Google Patents

高亲脂性生理活性物质的控释制剂 Download PDF

Info

Publication number
CN114945353A
CN114945353A CN202080072328.8A CN202080072328A CN114945353A CN 114945353 A CN114945353 A CN 114945353A CN 202080072328 A CN202080072328 A CN 202080072328A CN 114945353 A CN114945353 A CN 114945353A
Authority
CN
China
Prior art keywords
dosage form
physiologically active
highly lipophilic
substances
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072328.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·诺瓦克
J·J·诺瓦克
A·格拉维
M·文泽拉夫
S·巴托尔德
C·冈格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Advanced Drug Delivery Technology Co ltd
Original Assignee
Ed Advanced Drug Delivery Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Advanced Drug Delivery Technology Co ltd filed Critical Ed Advanced Drug Delivery Technology Co ltd
Publication of CN114945353A publication Critical patent/CN114945353A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080072328.8A 2019-10-16 2020-10-16 高亲脂性生理活性物质的控释制剂 Pending CN114945353A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203580.6 2019-10-16
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
CN114945353A true CN114945353A (zh) 2022-08-26

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072328.8A Pending CN114945353A (zh) 2019-10-16 2020-10-16 高亲脂性生理活性物质的控释制剂

Country Status (10)

Country Link
US (1) US20240139215A1 (enExample)
EP (2) EP3808341A1 (enExample)
JP (2) JP7778069B2 (enExample)
CN (1) CN114945353A (enExample)
AU (1) AU2020365443B2 (enExample)
BR (1) BR112022006643A2 (enExample)
CA (1) CA3157654A1 (enExample)
IL (1) IL292018A (enExample)
MX (1) MX2022004523A (enExample)
WO (1) WO2021074403A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929197A (zh) * 2019-10-16 2022-08-19 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021400338A1 (en) 2020-12-17 2023-07-13 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods
US12636296B1 (en) 2025-07-17 2026-05-26 Nalu Bio, Inc. Cannabinol analogs and their use as pharmacologically active agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
DE10296335T5 (de) * 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
WO2008024490A2 (en) * 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
WO2016023923A1 (en) * 2014-08-11 2016-02-18 Perora Gmbh Formulation comprising particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
JP2019137614A (ja) * 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10296335T5 (de) * 2001-02-14 2004-04-15 G W Pharma Ltd., Salisbury Pharmazeutische Formulierungen
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
CN1658840A (zh) * 2002-06-14 2005-08-24 Lts罗曼治疗方法有限公司 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型
WO2008024490A2 (en) * 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
WO2016023923A1 (en) * 2014-08-11 2016-02-18 Perora Gmbh Formulation comprising particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THAKKAR A L等人: "Solid dispersion approach for overcoming bioavailability problems due to polymorphism of nabilone, a cannabinoid derivative", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》, vol. 29, no. 1, pages 783 - 784, XP009150978 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929197A (zh) * 2019-10-16 2022-08-19 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂

Also Published As

Publication number Publication date
IL292018A (en) 2022-06-01
JP7778069B2 (ja) 2025-12-01
WO2021074403A1 (de) 2021-04-22
CA3157654A1 (en) 2021-04-22
AU2020365443A1 (en) 2022-06-02
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
US20240139215A1 (en) 2024-05-02
AU2020365443B2 (en) 2026-06-04
JP2022553653A (ja) 2022-12-26
JP2025182116A (ja) 2025-12-11
MX2022004523A (es) 2022-09-19
BR112022006643A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
JP7778069B2 (ja) 高親油性生理活性物質の放出制御製剤
JP2022534763A (ja) カンナビノイド製剤
WO2018058235A1 (en) Sustained release cannabinoid formulations
AU2013260246A2 (en) Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
US20230181484A1 (en) Uses and Formulations of Cannabinoids
EP4252745A1 (en) Water-soluble cannabinoid formulation and preparation method therefor
AU2022349666B2 (en) Cannabinoid formulation for oral administration
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
JP7850068B2 (ja) 高親油性生理活性物質の放出制御製剤
CN115843245A (zh) 大麻素的用途和制剂
CN110582278A (zh) 药物组合物及其用途
WO2022219198A1 (en) Formulations of cannabinoids
CA3005885A1 (en) Sustained release cannabinoid pellets
EP4074307B1 (en) Formulations of cannabinoids
CN117715626A (zh) 大麻素的制剂
JP2020533369A (ja) チモキノン含有組成物の調製法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination